Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 16/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923968 | 0.89 | HIF1A (0.50) | HIF1ACHRNA7ROCK1 | |
| SCHEMBL1571717 | 0.77 | RAB9A (0.54) | CHRNA7 | |
| SCHEMBL1571854 | 0.77 | RAB9A (0.54) | CHRNA7 | |
| SCHEMBL496329 | 0.75 | HIF1A (0.43) | HIF1ACHRNA7 | |
| SCHEMBL1572330 | 0.73 | HCRTR1 (0.41) | — | |
| SCHEMBL1572333 | 0.73 | HCRTR1 (0.41) | — | |
| SCHEMBL496256 | 0.72 | HIF1A (0.50) | HIF1ACHRNA7ROCK1 | |
| SCHEMBL29580510 | 0.71 | HIF1A (0.60) | HIF1A | |
| SCHEMBL20189383 | 0.70 | HIF1A (0.67) | HIF1ACHRNA7 | |
| SCHEMBL29581395 | 0.70 | HIF1A (0.67) | HIF1ACHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124636-A1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-26 | — | — | US | disclosed |
| EP-2094690-B1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124636-A1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CNR1 | HIF1A 532/4885CHRNA7 83/4885ROCK1 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.